Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.79 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055382 | 0.93 | HRH3 (0.83) | HRH3KEAP1NFE2L2KCNH2KDM4E | |
| SCHEMBL4547156 | 0.85 | HRH3 (0.79) | HRH3KEAP1NFE2L2KCNH2KDM4E | |
| SCHEMBL3052357 | 0.85 | HRH3 (0.72) | HRH3KEAP1NFE2L2KCNH2KDM4E | |
| SCHEMBL14922323 | 0.84 | HRH3 (0.66) | HRH3KEAP1NFE2L2KCNH2KDM4E | |
| SCHEMBL928390 | 0.84 | HRH3 (0.77) | HRH3KEAP1NFE2L2KCNH2KDM4E | |
| SCHEMBL12844521 | 0.84 | HRH3 (0.80) | HRH3KEAP1NFE2L2KCNH2KDM4E | |
| Hydrochloric Acid SCHEMBL9735260 | 0.82 | HRH3 (0.72) | HRH3KEAP1NFE2L2LMNAKDM4E | |
| SCHEMBL874146 | 0.82 | HRH3 (0.74) | HRH3KEAP1NFE2L2KCNH2LMNA | |
| SCHEMBL10662153 | 0.82 | HRH3 (0.77) | HRH3KEAP1NFE2L2KCNH2KDM4E | |
| SCHEMBL5156655 | 0.82 | LMNA (0.65) | HRH3LMNAL3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101939326-B | Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof | RWTH AACHEN UNIVERSITY | 2013-06-05 | — | — | CN | disclosed |
| US-8394979-B2 | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2013-03-12 | — | — | US | disclosed |
| CN-101939326-A | Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof | RWTH AACHEN | 2011-01-05 | — | — | CN | disclosed |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | THPO, MCL1, PPOX | HRH3 3145/4885KEAP1 997/4885NFE2L2 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.